Fudan University
1,617
404
473
329
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
2.1%
34 terminated/withdrawn out of 1617 trials
90.6%
+4.0% vs industry average
15%
239 trials in Phase 3/4
4%
14 of 329 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (1617)
SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete Response
Role: lead
Artificial Intelligence-assisted Primary Care for RSV Prevention (AIPC-RSV) in China
Role: lead
Vaccine Knowledge, Attitudes and Practices Among Men Who Have Sex With Men: a Global Cross-sectional Study
Role: lead
Dalpicilib-Enhanced vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer
Role: lead
Cryoablation Combined With Anlotinib Plus TQB2868 in Patients With Advanced Intrahepatic Cholangiocarcinoma
Role: lead
Collective Motivational Interviewing (CMI) for Adolescents With Internet Gaming Disorder
Role: collaborator
CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）
Role: lead
T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis
Role: lead
TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
Role: lead
Capecitabine in Low Risk Triple Negative Breast Cancer
Role: lead
Exploring the Impact of Diurnal Variation on Coagulation Function in Patients Undering Tumor Surgery
Role: lead
ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer
Role: lead
Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer
Role: lead
T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis
Role: lead
1-Week Versus 3-Week PBI
Role: lead
Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer
Role: lead
SREBF1 Polymorphism and Egg Yolk on Cardiovascular Disease Risk in Healthy Young Adults: a Randomised, Two-period, Single Blinded, Crossover Trial
Role: collaborator
Response-Adapted Omission of Nodal Boost In N3 Breast Cancer After Neoadjuvant Systemic Therapy
Role: lead
SCRT Combined With CAPOX and PD-1/CTLA4 Antibody for Early-stage Low Rectal Cancer
Role: lead
Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis
Role: lead